| Nagoya University |
2011 |
Glioblastoma, human (U251SP) |
Normal brain astrocytes, human (ACBRI-371) |
Selective apoptosis (caspase 3/7), AKT kinase down-regulation) |
%95
|
| 2012 |
Normal fibroblasts, human (WI-38) |
Down-regulation of survival/proliferation signaling networks, selectivity |
%96
|
| 2013 |
Ovarian cancer (paclitaxel/cisplatin resistant) |
N/A |
Anti-tumor effects demonstrated, in vitro and in vivo
|
%98
|
| 2014 |
Ovarian clear cell carcinoma (TOV21G, ES-2, SKOV3) |
Peritoneal mesothelial cells, human |
CCC selective apoptosis |
%99
|
| 2015 |
Lung (A549), liver (HepG2), and breast (MCF-7) cancer lines |
N/A |
Media composition effects; apoptosis (mitochondrial dysfunction) |
%100
|
| 2015 |
Gastric cancer (NUGC4, CS-2-NU, MKN28, MKN45) |
Normal fibroblasts, human (WI-38) |
Selective apoptosis (caspase 3/7); cell line effects |
%101
|
| 2015 |
Pancreatic cancer (PANC-1, Capan-2, BxPC-3, MIA PaCa-2) |
Normal pancreatic duct epithelial cells, human (HPDE6/C7) |
Selective apoptosis (caspase 3/7, cell morphology); in vitro and in vivo
|
%103
|
| Leibniz Institute |
2015 |
Melanoma (SK-Mel-147) |
N/A |
Cell migration and adhesion more affected than apoptosis |
%83
|
| George Washington University |
2014 |
Glioblastoma, human (U87) |
N/A |
FBS concentration and temperature storage effects |
%61
|
| 2015 |
Glioblastoma (U87) and breast cancer (MDA-MB-231, MCF-7) |
N/A |
Potency based on cell line, optimized plasma treatment parameters, cysteine involvement |
%66
|
| 2016 |
Glioblastoma (U87), pancreatic, and (PA-TU-8988T) breast (MDA-MB-231) cancers |
N/A |
Amino acid scavenging of ROS and implications on potency and storage |
%67
|
